We observed that only recipients receiving Il17af-/-, but not Il17a-/-, Il17f-/- CD4+ T cells, developed an aggravated GVHD as compared to WT controls (Fig 2A and 2B). This evidence concerns the gene IL17F and graft versus host disease.